Effects of Particulate Matter on the Pulmonary Function and Acute Exacerbation of COPD and Asthma

NCT03193879 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 505

Last updated 2021-09-21

No results posted yet for this study

Summary

Particulate matter(PM) exposure has been shown to increase the morbidity and mobility of a variety of respiratory diseases, including COPD and asthma. This study focus on the effects of PM on the pulmonary function and acute exacerbation of COPD and asthma patients in China, where PM exposure is much heavier than the United States and European countries.

Conditions

  • Pulmonary Function

Sponsors & Collaborators

  • Xinjiang Autonomous Region People 's Hospital

    collaborator UNKNOWN
  • Cangzhou Central Hospital

    collaborator OTHER
  • Chengdu sixth People 's Hospital

    collaborator UNKNOWN
  • Chengde Central Hospital

    collaborator OTHER_GOV
  • Beijing Fengtai Hospital

    collaborator UNKNOWN
  • The Affiliated Hospital of Medical College, Ningbo University

    collaborator OTHER
  • Changzhi Medical College

    collaborator OTHER
  • Beijing Boai Hospital

    collaborator OTHER
  • Wuhu County Traditional Chinese Medicine Hospital

    collaborator OTHER
  • The First People's Hospital of Jingzhou

    collaborator OTHER
  • Fujian Provincial Hospital

    collaborator OTHER
  • Harbin Zhongshan Asthma Hospital

    collaborator UNKNOWN
  • Rizhao Hospital of Chinese Traditional Medicine

    collaborator UNKNOWN
  • 3201 Hospital in Hanzhong

    collaborator OTHER
  • Sir Run Run Shaw Hospital

    collaborator OTHER
  • Chengdu Fifth People's Hospital

    collaborator OTHER
  • First People 's Hospital of Changsha

    collaborator UNKNOWN
  • Chongqing Jiangjin Central Hospital

    collaborator UNKNOWN
  • the Affiliated hospital of Guilin medical university, China

    collaborator UNKNOWN
  • Jiangxi People 's Hospital

    collaborator UNKNOWN
  • Chinese People 's Liberation Army Navy Anqing Hospital

    collaborator UNKNOWN
  • The Affiliated Hospital of Inner Mongolia Medical University

    collaborator OTHER
  • Yancheng Dafeng People 's Hospital

    collaborator UNKNOWN
  • ShuGuang Hospital

    collaborator OTHER
  • The First Affiliated Hospital of the Fourth Military Medical University

    collaborator OTHER
  • Taizhou Hospital

    collaborator OTHER
  • The Second Affiliated Hospital of Harbin Medical University

    collaborator OTHER
  • Third Affiliated Hospital of Xinjiang Medical University

    collaborator OTHER
  • First People 's Hospital of Kunming

    collaborator UNKNOWN
  • First People 's Hospital of Yunnan

    collaborator UNKNOWN
  • Pingxiang People 's Hospital

    collaborator UNKNOWN
  • Northern Jiangsu People 's Hospital

    collaborator UNKNOWN
  • Xiangya Hospital of Central South University

    collaborator OTHER
  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    collaborator OTHER
  • Second Hospital of Jilin University

    collaborator OTHER
  • The Second Economic Hospital of Xinjiang Uygur Autonomous Region

    collaborator UNKNOWN
  • Shanghai Zhongshan Hospital

    collaborator OTHER
  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193879 on ClinicalTrials.gov